Stockscreener 앱 받기
138.98
0.01%
-0.02
전일 마감가:
$139.00
열려 있는:
$138.03
하루 거래량:
630.15K
Relative Volume:
0.93
시가총액:
$5.89B
수익:
$2.81B
순이익/손실:
$-294.68M
주가수익비율:
-6.093
EPS:
-22.8098
순현금흐름:
$232.59M
1주 성능:
+1.76%
1개월 성능:
+10.02%
6개월 성능:
+4.26%
1년 성능:
+8.48%
1일 변동 폭
$0.00
$0.00
1주일 범위
$130.48
$140.30
52주 변동 폭
$100.18
$145.00
텔레플렉스 Stock (TFX) Company Profile
명칭
Teleflex Incorporated
전화
610-225-6800
주소
550 E SWEDESFORD RD, WAYNE, PA
Compare TFX vs ISRG, BDX, RMD, ALC, WST
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TFX
Teleflex Incorporated
|
138.98 | 5.89B | 2.81B | -294.68M | 232.59M | -22.81 |
ISRG
Intuitive Surgical Inc
|
444.18 | 156.92B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
195.16 | 53.16B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
250.17 | 35.18B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
69.83 | 33.76B | 10.63B | 819.00M | 1.59B | 1.6577 |
WST
West Pharmaceutical Services Inc
|
403.64 | 28.41B | 3.22B | 542.70M | 458.00M | 7.4805 |
텔레플렉스 Stock (TFX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2026-07-28 | 개시 | UBS | Neutral |
| 2026-07-09 | 개시 | BMO Capital Markets | Outperform |
| 2026-06-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2026-05-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-04-13 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2026-03-27 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2026-01-27 | 업그레이드 | Needham | Hold → Buy |
| 2025-03-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-02-28 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-02-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2025-02-27 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-07-01 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-12-04 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-21 | 다운그레이드 | Needham | Buy → Hold |
| 2023-05-30 | 개시 | CL King | Buy |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-14 | 재개 | Stephens | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-29 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-07-06 | 개시 | Wolfe Research | Outperform |
| 2022-05-09 | 개시 | BofA Securities | Neutral |
| 2022-04-13 | 개시 | Truist | Hold |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-07 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-09-07 | 재개 | Raymond James | Outperform |
| 2021-07-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-01-06 | 재확인 | Needham | Buy |
| 2020-11-02 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-01-31 | 재확인 | Needham | Buy |
| 2019-08-02 | 재확인 | Needham | Buy |
| 2019-06-11 | 개시 | Wells Fargo | Outperform |
| 2019-04-24 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2019-02-22 | 재확인 | Needham | Strong Buy |
| 2018-10-16 | 개시 | Barclays | Equal Weight |
| 2018-09-10 | 업그레이드 | Needham | Buy → Strong Buy |
| 2018-08-03 | 재확인 | Needham | Buy |
| 2018-05-14 | 재확인 | Needham | Buy |
| 2018-05-04 | 재확인 | Needham | Buy |
| 2018-04-04 | 개시 | Goldman | Neutral |
| 2017-11-10 | 재개 | Piper Jaffray | Overweight |
| 2017-11-03 | 재확인 | Needham | Buy |
| 2017-09-08 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-09-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-06 | 재확인 | Needham | Buy |
| 2017-03-07 | 개시 | Needham | Buy |
| 2017-01-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-07-12 | 다운그레이드 | KeyBanc Capital Mkts | Overweight → Sector Weight |
모두보기
텔레플렉스 주식(TFX)의 최신 뉴스
Benign Prostatic Hyperplasia Treatment Device Market Size, Forecast, 2034 - Straits Research
Continuous Bladder Irrigation Devices Market Size, Forecast, Demand, Opportunities, 2034 - Straits Research
FDA approves Teleflex cardiac treatment - Pennsylvania Business Report -
Neurogenic Detrusor Overactivity Market Report Examines Industry Trends, Growth Drivers And Future Outlook - openPR.com
Teleflex Incorporated Announces Fda Breakthrough Device Designation for Freesolve Resorbable Magnesium Scaffold - marketscreener.com
Teleflex wins FDA breakthrough status for heart scaffold device - Investing.com India
FDA grants Teleflex breakthrough device status for coronary scaffold - StreetInsider
Teleflex Announces FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold - Business Wire
Teleflex Announces Third Quarter 2026 Earnings Conference Call Information - Business Wire
Teleflex (TFX) Expected to Release Quarterly Earnings on Thursday - MarketBeat
Teleflex Incorporated $TFX Shares Sold by State of Alaska Department of Revenue - MarketBeat
Teleflex Incorporated $TFX Shares Sold by Cooke & Bieler LP - MarketBeat
Teleflex (NYSE:TFX) Shares Cross Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Teleflex investors brace for earnings as turnaround story builds By Investing.com - Investing.com Australia
CMA Seeks Views On Intersurgical's Teleflex Deal - Law360
Truist cuts Teleflex target from USD 150 to USD 142 for Teleflex stock - ad-hoc-news.de
REGCompetition and MktsMerger Update: Intersurgical / Teleflex - TradingView
Truist cuts Teleflex target to USD 142 from USD 150 for Teleflex stock - ad-hoc-news.de
Teleflex Incorporated (TFX) Stock Forecasts - Yahoo! Finance Canada
Teleflex Inc. stock outperforms competitors on strong trading day - MarketWatch
How Is Teleflex Incorporated (NYSE:TFX) Reshaping Its Portfolio? - Kalkine Media
Teleflex Inc. stock outperforms competitors on strong trading day - MarketWatch
Teleflex Incorporated (TFX) Stock forecasts - Yahoo Finance UK
Teleflex Incorporated (TFX) Stock Forecasts - Yahoo Finance
Teleflex Incorporated (TFX) Stock forecasts - Yahoo Finance UK
Teleflex Inc. stock outperforms competitors despite losses on the day - MarketWatch
Disposable Nasal Airway Tubes Market Forecast to 2035, Driven by Rising Surgical Volumes and Aging Demographics - IndexBox
Balloon Inflation Devices Market To 2035: Minimally Invasive Procedures Fuel GrowthNews and Statistics - IndexBox
Pulmonary Artery Catheters Market Forecast to 2035: Demand to Accelerate on Rising High-Risk Cardiac Procedures - IndexBox
Why Is Teleflex (NYSE:TFX) Drawing Fresh Healthcare Attention? - Kalkine Media
Teleflex completes enrollment in coronary scaffold study By Investing.com - Investing.com Canada
Teleflex completes enrollment in BIOMAG-LL magnesium scaffold study - StreetInsider
102 patients joined a study of longer artery supports designed to be absorbed - Stock Titan
Teleflex Catheters Linked to 70% Lower Infection Hazard - MyChesCo
Epidural Needles Market To 2035: Growth Driven by Rising Obstetric Anesthesia DemandNews and Statistics - IndexBox
Teleflex Incorporated (TFX) Stock forecasts - Yahoo Finance Singapore
China Airway Management Market Forecast to 2033Airway Management Tubes and Intubation Accessories | Revenue, Volume, Pricing, Company Share, and Growth Opportunities - GlobeNewswire Inc.
Teleflex Q3 2026 Earnings Date and Estimates - MarketBeat
Bruker Gains 66.3% in a Year: What's Driving the Rally? - Zacks Investment Research
Full Transcript: Teleflex Q2 2026 Earnings Call - Benzinga
Teleflex Incorporated (TFX) Stock Forecasts - Yahoo Finance
Teleflex Incorporated (TFX) Stock Forecasts - Yahoo! Finance Canada
Reasons to Add Globus Medical Stock to Your Portfolio Now - Zacks Investment Research
Charles River Gains 75.8% in a Year: What's Driving the Rally? - Zacks Investment Research
TFX or SONVY: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Is It Prudent to Add Teleflex Stock to Your Portfolio Now? - Zacks Investment Research
Teleflex Incorporated (NYSE:TFX) Stock Now Rated "Moderate Buy" by Wall Street Brokerages - MarketBeat
Teleflex Inc. stock underperforms Friday when compared to competitors - MarketWatch
Boston Scientific's MedSurg Diversification Bolsters Growth Prospects - Zacks Investment Research
Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology - Business Wire
텔레플렉스 (TFX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.41%
1.48%
자본화:
|
볼륨(24시간):